Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04382053
Recruitment Status : Completed
First Posted : May 11, 2020
Results First Posted : November 30, 2021
Last Update Posted : May 2, 2022
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This clinical study was designed to assess the efficacy and safety of DFV890 for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infected patients with coronavirus disease 2019 (COVID-19) pneumonia and impaired respiratory function.

Condition or disease Intervention/treatment Phase
COVID-19 Pneumonia, Impaired Respiratory Function Drug: DFV890 Drug: Standard of Care (SoC) Phase 2

Detailed Description:

This was a Phase II, randomized, controlled, open label multi-center study to assess the efficacy and safety of DFV890 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function.

The study consisted of four distinct study periods:

Screening / Baseline visit (Day -1 to 1): lasted up to a maximum of 24 hours and comprised a screening / baseline assessment. This visit was used to confirm that the study inclusion and exclusion criteria were met and served as baseline assessment prior to randomization.

Treatment period (Day 1-15): Participants were randomized as soon as possible, but within a maximum of 24 hours after screening in a 1:1 ratio receiving either DFV890 in addition to standard of care (SoC) or SoC alone. Participants in the investigational treatment arm received DFV890 administered for a total of 14 days in addition to SoC. Participants in the control arm received SoC alone. Study assessments were conducted every 2 days for hospitalized participants.

The End of Treatment (EOT) visit took place on Day 15. If participants were discharged from the hospital prior to Day 15, assessments on the day of discharge were performed according to the schedule listed under Day 15; participants continued to take the investigational treatment at home to complete the 14-day treatment period and the participants returned to the site for the Day 15/EOT assessment. If a hospital visit was not possible at Day 15, then home nursing services were used to support the last visit.

Follow-up (Day 16-29): After completion of the treatment period, participants were observed until Day 29 or discharged from hospital, whichever was sooner. Study assessments were conducted every 2 days for hospitalized participants. If participants were discharged from hospital prior to Day 29, a study visit conducted by telephone was performed on Day 29.

30-day safety follow-up assessment (Day 45): A follow-up visit for safety was conducted by telephone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 143 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function
Actual Study Start Date : May 27, 2020
Actual Primary Completion Date : December 10, 2020
Actual Study Completion Date : December 24, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: DFV890 + SoC
DFV890 was administered for 14 days in addition to SoC.
Drug: DFV890
DFV890 tablets administered for 14 days in addition to SoC.

Drug: Standard of Care (SoC)
SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.

Active Comparator: Standard of Care (SoC)
SoC was used as an active comparator arm.
Drug: Standard of Care (SoC)
SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.




Primary Outcome Measures :
  1. APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier) [ Time Frame: up to Day 15 ]

    The APACHE II ("Acute Physiology And Chronic Health Evaluation II") is a severity-of-disease classification system. An integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death. In practice, it is rare for any participant to accumulate more than 55 points.

    APACHE II score was measured on Day 15 or on the day of discharge (whichever was earlier). Participants who died on Day 15 or earlier were assigned the highest observed APACHE II score of any of the participants at any time during the trial (worst case imputation for deaths). Missing data values of the parameters required for the derivation of the APACHE II score were replaced by the last available assessment.



Secondary Outcome Measures :
  1. Serum C-reactive Protein (CRP) Levels [ Time Frame: Days 2, 4, 6, 8, 10, 12, 14 and 15 ]
    C-reactive protein (CRP) is a blood test marker for inflammation in the body. It was analyzed on a log-scale fitting a repeated measures mixed model including treatment group, study day, the three stratification factors and log transformed baseline CRP as a covariate. Values reported were back-transformed to original scale.

  2. Clinical Status Over Time [ Time Frame: Baseline, days 2, 4, 6, 8, 10, 12, 14, 15, 17, 19, 21, 23, 25, 27 and 29 ]

    Clinical status was measured with World Health Organization (WHO) 9-point ordinal scale.

    The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, renal replacement therapy, extracorporeal membrane oxygenation). - Patients who die have a score 8.

    Missing data values were handled as follows: For participants who died prior to Day 29, the score for death was imputed for all following visits up to and including day 29. For all the other participants, last observation carried forward was applied up to and including Day 29.


  3. Number of Participants Not Requiring Mechanical Ventilation for Survival [ Time Frame: Until Day 15 (Assessments on Days 2, 4, 6, 8, 10, 12, 14 and 15) and until Day 29 (Assessments on Days 17, 19, 21, 23, 25, 27 and 29) ]

    Number of participants not requiring mechanical ventilation for survival until Day 15 and Day 29: defined by WHO 9-point ordinal scale score of < 6 points at all time points assessments.

    The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support). - Patients who die have a score 8.

    Missing data values were handled as follows: For participants who died prior to Day 29, the score for death was imputed for all following visits up to and including day 29. For all the other participants, last observation carried forward was applied up to and including Day 29.


  4. Number of Participants With at Least One-point Improvement From Baseline in Clinical Status [ Time Frame: Baseline, Day 15 and Day 29 ]

    Number of participants with at least one-point improvement from baseline in clinical status, which was measured with WHO 9-point ordinal scale.

    The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support). - Patients who die have a score 8.

    Missing data values were handled as follows: For participants who died prior to Day 29, the score for death was imputed for all following visits up to and including day 29. For all the other participants, last observation carried forward was applied up to and including Day 29.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients aged 18-80 years inclusive at screening.
  • Clinically diagnosed with the SARS-CoV-2 virus by polymerase chain reaction (PCR) or by other approved diagnostic methodology within 7 days prior to randomization.
  • Hospitalized with COVID-19-induced pneumonia evidenced by chest X-ray, computed tomography scan (CT scan) or magnetic resonance scan (MR scan), taken within 5 days prior to randomization (within 24 hours in patients in the Netherlands).
  • Impaired respiratory function, defined as peripheral oxygen saturation (SpO2) ≤93% on room air or partial pressure of oxygen (PaO2) / fraction of inspired oxygen (FiO2) <300 millimeter of mercury (mmHg) at screening. For cities located at altitudes greater than 2500 m above sea level, these will be substituted with SpO2 <90% and PaO2/FiO2 <250 mmHg.
  • APACHE II score of ≥10 at screening.
  • C-reactive protein (CRP) ≥20 mg/L and/or ferritin level ≥600 μg/L at screening.
  • Body mass index of ≥18 to <40kg/m2 at screening.

Exclusion Criteria:

  • Suspected active or chronic bacterial (including Mycobacterium tuberculosis), fungal, viral, or other infection (besides SARS-CoV-2).
  • In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatment.
  • Intubated prior to randomization.
  • Previous treatment with anti-rejection and immunomodulatory drugs within the past 2 weeks, or within the past 30 days or 5 half-lives (whichever is the longer) for immunomodulatory therapeutic antibodies or prohibited drugs, with the exception of hydroxychloroquine, chloroquine or corticosteroids:

For COVID-19 infection, ongoing corticosteroid treatment is permitted at doses as per local SoC.For non-COVID-19 disorders, ongoing corticosteroid treatment is permitted at doses up to and including prednisolone 10 mg daily or equivalent.

In patients in the Netherlands only, the use of hydroxychloroquine and/or chloroquine in the past 2 weeks are exclusionary.

  • Serum alanine transaminase (ALT) or aspartate transaminase (AST) >5 times upper limit of normal detected within 24 hours at screening or at baseline (according to local laboratory reference ranges) or other evidence if severe hepatic impairment (Child-Pugh Class C).
  • Absolute peripheral blood neutrophil count of ≤1000/mm3.
  • Estimated GFR (eGFR) ≤30 mL/min/1.73m2 (based on CKD-EPI formula).
  • Patients currently being treated with drugs known to be strong or moderate inducers of isoenzyme CYP2C9 and/or strong inhibitors of CYP2C9 and/or strong inducers of cytochrome P450, family 3, subfamily A (CYP3A) and the treatment cannot be discontinued or switched to a different medication prior to starting study treatment.
  • Patients with innate or acquired immunodeficiencies.
  • Patients who have undergone solid organ or stem cell transplantation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04382053


Locations
Layout table for location information
Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina, C1180AAX
Novartis Investigative Site
Buenos Aires, Argentina, B1846BMF
Brazil
Novartis Investigative Site
Porto Alegre, RS, Brazil, 90020-090
Novartis Investigative Site
Sao Paulo, SP, Brazil, 04029-000
Denmark
Novartis Investigative Site
Hvidovre, Denmark, 2650
Germany
Novartis Investigative Site
Regensburg, Bavaria, Germany, 93053
Novartis Investigative Site
Hannover, Germany, 30625
Novartis Investigative Site
Wuerzburg, Germany, 97080
Hungary
Novartis Investigative Site
Budapest, Hungary, 1121
India
Novartis Investigative Site
Coimbatore, Tamil Nadu, India, 641028
Novartis Investigative Site
Kolkata, West Bengal, India, 700099
Novartis Investigative Site
New Delhi, India, 110029
Novartis Investigative Site
New Delhi, India, 110075
Mexico
Novartis Investigative Site
Ciudad de Mexico, Mexico CP, Mexico, 14080
Novartis Investigative Site
Monterrey, Nuevo Leon, Mexico, 64460
Netherlands
Novartis Investigative Site
Harderwijk, Netherlands, 3840 AC
Peru
Novartis Investigative Site
San Martin de Porres, Lima, Peru, 31
Novartis Investigative Site
San Miguel, Lima, Peru, 32
Russian Federation
Novartis Investigative Site
Barnaul, Russian Federation, 656045
Novartis Investigative Site
Chelyabinsk, Russian Federation, 454021
Novartis Investigative Site
Ekaterinburg, Russian Federation, 620035
Novartis Investigative Site
Krasnoyarsk, Russian Federation, 660049
Novartis Investigative Site
Moscow, Russian Federation, 119991
Novartis Investigative Site
Ryazan, Russian Federation, 390039
Novartis Investigative Site
Saint Petersburg, Russian Federation, 193079
Novartis Investigative Site
St Petersburg, Russian Federation, 199106
South Africa
Novartis Investigative Site
George, Western Cape, South Africa, 6529
Spain
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08036
Novartis Investigative Site
Madrid, Spain, 28006
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis pharmaceuticals Novartis Pharmaceuticals
  Study Documents (Full-Text)

Documents provided by Novartis ( Novartis Pharmaceuticals ):
Study Protocol  [PDF] June 22, 2020
Statistical Analysis Plan  [PDF] December 17, 2020

Additional Information:
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04382053    
Other Study ID Numbers: CDFV890D12201
2020-001870-32 ( EudraCT Number )
First Posted: May 11, 2020    Key Record Dates
Results First Posted: November 30, 2021
Last Update Posted: May 2, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
COVID-19 pneumonia
SARS-CoV-2
APACHE II
DFV890
inflammasome
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Pneumonia
Respiratory Insufficiency
Respiratory Tract Infections
Infections
Pneumonia, Viral
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders